AI Software for same-day dementia screening

Using EEG visuospatial deficits to estimate clinical endpoints of dementia
Add us to your clinic today!

Reduce inconclusive test results with efficient dementia screening

Vistim Labs’ high-resolution biomarkers correlate with traditional PET/CSF & cognitive endpoints

Would you like to publish together as research partners?

Collaborate with us Today

Vision

We see a new standard of care where patients, clinicians, and researchers can quickly and easily perform dementia screening in-office, enabling opportunities to intervene to save individuals, families, and communities.

Mission

To increase patient access to care and to empower clinical decision making ability with our dementia screening tools. Our AI estimates clinical endpoints of neurodegeneration by identifying visuospatial & cognitive deficits from stimulated EEG patterns that indicate specific levels of amyloid and tau protein accumulation as well as cognitive impairment.

Learn more about our science

Relevant Press & Publications

Vistim Labs presents at AAIC 2023

VISTIM LABS UNVEILS NOVEL BIOMARKERS AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2023

Read more
Vistim Labs Wins 1st at Inventures 2023

VISTIM LABS WINS 1ST PLACE & $10K GRANT AT INVENTURES HEALTH COMPETITION

Read more
Vistim Labs EEG evidence separating neurodegenerative endpoints

VISTIM LABS PUBLISHES NEW FINDINGS IN ALZHEIMER’S RESEARCH AND THERAPY JOURNAL

Read more
Vistim Labs wins 1st at Startup San Diego

VISTIM LABS WINS 1ST PLACE & $10K GRANT AT STARTUP SAN DIEGO COMPETITION

Read more
Vistim Labs graduates from PharmStars accelerator

VISTIM LABS 1 OF 11 INVITED TO EXCLUSIVE ACCELERATOR, PHARMSTARS

Read more
James Hamet publishes findings of mental fatigue in truck drivers

CEO JAMES HAMET PUBLISHED FOR NOVEL EEG BIOMARKERS OF MENTAL FATIGUE

Read more